Research & Development
-
Permission granted by Courtesy of Helus Pharma
Q&A // First 90 DaysHow Helus’ new CEO plans to scale its psychedelic drug pipeline
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?
By Kelly Bilodeau • Aug. 18, 2026 -
Getty Images
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
By Alexandra Pecci • Aug. 17, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Courtesy of BMS
BMS builds big in Texas; Regeneron backs would-be rival
BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.
By PharmaVoice Staff • Aug. 14, 2026 -
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
By Kelly Bilodeau • Aug. 14, 2026 -
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
By Alexandra Pecci • Aug. 13, 2026 -
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Getty Images
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
By Kelly Bilodeau • Aug. 10, 2026 -
Sascha Schuermann/Getty Images via Getty Images
Why Big Pharma is chasing the industry’s most-powerful supercomputer
BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
By Alexandra Pecci • Aug. 7, 2026 -
Getty Images
FDA allows unique endpoint in rare disease study
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
By Alexandra Pecci • Aug. 5, 2026 -
Permission granted by Merck & Co.
Q&AMerck is pharma’s most patent-exposed company. Now it’s reinventing itself.
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
By Meagan Parrish • Aug. 5, 2026 -
Getty Images
Three potential takeover targets in psychedelics
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
By Kelly Bilodeau • Aug. 4, 2026 -
Permission granted by Evonik
Sponsored by EvonikThe future of oral drug delivery must be sustainable
How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.
By Lucas Cusin, Global Technical Marketing Manager, Oral Drug Delivery Solutions, Evonik & Thilo Krapfl, Head of Product Line Oral Drug Delivery Solutions, Evonik • Aug. 3, 2026 -
Getty Images
Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision
Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.
By PharmaVoice Staff • July 31, 2026 -
Permission granted by Telix Pharmaceuticals
Q&AHow Telix landed a $2.1 billion radiopharma deal with Regeneron
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
By Alexandra Pecci • July 30, 2026 -
Permission granted by Caribou Biosciences
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
By Kelly Bilodeau • July 29, 2026 -
Scott Olson via Getty Images
Kalshi is expanding online betting in drug R&D — unless detractors can stop it
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.
By Susanna Vogel • July 28, 2026 -
Getty Images
Why 3 secretive biotechs are keeping their science close to the chest
Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.
By Kelly Bilodeau • July 27, 2026 -
Getty Images
Lilly’s leap into psychedelics; peptides in the spotlight
Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.
By PharmaVoice Staff • July 24, 2026 -
Getty Images
What’s in the FDA’s latest batch of rejection letters
A look at two recent CRLs demonstrate the tension and discrepancies between how companies and the agency communicate drug rejections.
By Alexandra Pecci • July 23, 2026 -
Getty Images
OpinionBiopharma challenges leaders want to tackle
Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.
By Meagan Parrish • July 23, 2026 -
Permission granted by Eli Lilly
Q&ABeyond weight loss: Lilly aims for leadership in brain science
Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.
By Kelly Bilodeau • July 21, 2026 -
Michel Lunanga / Stringer via Getty Images
As the Ebola outbreak rages, new treatments are headed into trials. Will they work?
The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.
By Alexandra Pecci • July 20, 2026 -
Permission granted by Banyan BioInnovations
Long days, dinners with copious alcohol, and the hunt for emerging assets in China
Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.
By Meagan Parrish • July 17, 2026 -
Getty Images
Biotech SpotlightThis startup thinks humans in clinical trials could become a ‘formality’
Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.
By Alexandra Pecci • July 16, 2026 -
Getty Images
How well are AI-discovered drugs faring in the clinic?
Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.
By Kelly Bilodeau • July 15, 2026
